PTC Therapeutics, Inc. (PTCT)
Current
- (-)
After Hours
Rating Performance
Rating Return
+0.0% vs
Rating Accuracy
0.0% (0 of 0*)
Rating Return
+0.0% vs
Rating Accuracy
0.0% (0 of 0*)
Rating Return
+0.0% vs
Rating Accuracy
0.0% (0 of 0*)
Rating Return
-12.49% vs
Rating Accuracy
50.0% (1 of 2*)
FV Performance
FV Accuracy
0 Hits (0.0% Hit Rate)
FV Avg. Distance
+92.37%
FV Accuracy
0 Hits (0.0% Hit Rate)
FV Avg. Distance
+79.9%
FV Accuracy
0 Hits (0.0% Hit Rate)
FV Avg. Distance
+92.93%
FV Accuracy
12 Hits (24.49% Hit Rate)
FV Avg. Distance
+70.79%
About
CEO
Stuart W. Peltz
Employees
761
Industry
Neurology Biopharmaceuticals
Sector
Healthcare
Headquarters
South Plainfield
Exchange
NASDAQ
Website
http://www.ptcbio.comSummary Stats
Market Cap
2.86B
Revenue
569M
Net Income
-522M
EPS
-$7.38
Price-to-Earnings
-5.44
Price-to-Book
-31.59
Debt-to-Equity
-20.87
News
Analyst Ratings
Price targets projected by 12 analysts
High
$90.00
Average
$61.58
Low
$45.00
Ratings calculated by 13 analysts
Buy
7
Hold
6
Sell
0
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q1 2022
Missed by -$0.27
-$1.78 -17.9%
-1.51
-1.83
Up 2%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--